Clinical Trials Directory

Trials / Unknown

UnknownNCT05199818

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

Efficacy and Safety of Palonosetron HCl Buccal Film Versus IV Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
328 (estimated)
Sponsor
Xiamen LP Pharmaceutical Co., Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.

Detailed description

This is a phase 3 randomized, double-blind, parallel group study designed to evaluate the efficacy and safety of palonosetron HCL buccal film versus IV palonosetron for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy (MEC). Subjects are randomized into two treatment groups, one with the experimental study drug palonosetron in buccal film, the other one with the control treatment using Palonosetron hydrochloride IV injection. Palonosetron PK will be assessed in a subgroup of each treatment group (two sample points, 10% of subjects).

Conditions

Interventions

TypeNameDescription
DRUGPalonosetron HCl Buccal Film 0.5 mgPalonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
DRUGIV Palonosetron 0.25 mgIV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1

Timeline

Start date
2022-03-01
Primary completion
2023-09-01
Completion
2023-11-01
First posted
2022-01-20
Last updated
2023-01-20

Locations

13 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05199818. Inclusion in this directory is not an endorsement.